Background: In septic shock, chronic antihypertensive medications are held acutely. Vasopressors are often required to maintain blood pressure. The effect of chronic exposure to antihypertensive therapies on vasopressor dosing in septic shock is not known. Objective: To determine the effects of chronic exposure to antihypertensive therapies, specifically β-blockers and angiotensin-converting enzyme (ACE) inhibitors, on cumulative vasopressor dosing in septic shock. Methods: This was a retrospective cohort review, with data collected from routine care. Patients admitted to the medical intensive care unit with septic shock and vasopressor use were included and divided into 4 groups based on chronic medication use: (1) no β-blocker or ACE inhibitor, (2) β-blocker only, (3) ACE inhibitor only, and (4) β-blocker and ACE inhibitor. Cumulative vasopressor dose at 48 hours was assessed. Demographics, comorbid conditions, suspected site of infection, disease severity, mortality, and concomitant therapies were evaluated between groups. , 19h [6-25]; β-blocker and ACE inhibitor, 30h ; P = 0.031). Comorbid conditions, suspected infection sites, disease severity, mortality, and concomitant therapies were similar. Conclusions: Chronic β-blocker, ACE inhibitor use, or the combination of both did not affect cumulative vasopressor dose at 48 hours in septic shock. However, prior-to-admission medications may affect total time of vasopressor use.
Introduction
Sepsis, defined as life-threatening organ dysfunction caused by a dysregulated host response to infection, is a leading cause of mortality worldwide.
1,2 Septic shock is a more severe subset of sepsis in which underlying circulatory and cellular metabolism abnormalities are profound enough to substantially increase mortality and is identified by hypotension, hypoperfusion, and the requirement for vasopressor therapy. 1 Patients with septic shock often have a multitude of preexisting comorbidities (ie, hypertension, heart failure, diabetes, history of myocardial infarction, or stroke) that necessitate the use of chronic β-blockers or angiotensin-converting enzyme (ACE) inhibitors prior to admission to the hospital. These medications may alter the body's compensatory sympathetic β-receptors and renin-angiotensin-aldosterone system, systems responsible for blood pressure and heart rate control. 3, 4 Although the mechanisms for phenotype alterations are not well understood, in animal models, selective β1-adrenoceptor blockade has demonstrated anti-inflammatory and cardioprotective effects. 5 Similarly, ACE inhibition has demonstrated anti-inflammatory effects in animal models by blocking lipopolysaccharide-induced inflammatory response and protecting against acute lung injury associated with endotoxinemia. 1 Rush University Medical Center, Chicago, IL, USA Furthermore, associative human clinical data have suggested an improved survival when on chronic β-blockers or ACE inhibitor in sepsis or septic shock. 3, 4, 7 The use of catecholamine vasopressors, although often necessary as an emergency stabilization measure, have been associated with adverse events (ie, new onset atrial fibrillation, increased cellular metabolism, and mortality) and, therefore, are recommended to be used at the lowest dose and duration necessary to stabilize the patient. [8] [9] [10] [11] [12] What remains unknown is the effect of chronic exposure to antihypertensive therapies, specifically β-blockers and ACE inhibitors, on therapies that stimulate sympathetic pathways, such as vasopressors, to maintain blood pressure in septic shock. Because patients presenting with septic shock frequently have comorbidities that necessitate use of these chronic medications, it is important for practitioners to understand the clinical response of the various host dysregulations and underlying circulatory and cellular metabolism abnormalities to be able to develop a timely, patient-specific care plan that accounts for the effects of their chronic medications. Therefore, we hypothesize that chronic β-blocker or ACE inhibitor therapy is associated with decreased cumulative doses of vasopressors administered in the first 48 hours of septic shock.
Methods

Study Design, Patients, and Definitions
This study was retrospective, and data were collected from routine care at a tertiary academic medical center in Chicago, IL. Institutional Review Board approval was obtained, and all necessary regulations and procedures were in compliance. Patients were reviewed from January 1, 2012, to August 1, 2016. A list of ICU patients was generated by the corresponding ICD-9 (785.52) and ICD-10 (R65.21) codes for septic shock. Adult patients 18 years of age or older admitted to the medical intensive care unit (MICU) with septic shock who received treatment with a vasopressor were assessed for inclusion. Patients were divided into 4 groups: (1) no β-blocker or ACE inhibitor, (2) β-blocker only, (3) ACE inhibitor only, and (4) β-blocker and ACE inhibitor. Medications prior to admission were reconciled by hospital staff, and unless noted in admission progress notes, patients were assumed to be compliant. Septic shock was defined in accordance with current recommendations as a more severe subset of sepsis in which underlying circulatory and cellular metabolism abnormalities are profound enough to substantially increase mortality and is identified by hypotension, hypoperfusion, and the requirement for vasopressor therapy. 1 Following inpatient admission, patients with vasopressor medications recorded as "given" in the first 48 hours of septic shock were included. Initiation of vasopressors was considered the onset of septic shock. Patients were excluded if they were pregnant, transferred from an outside hospital on vasopressors, admitted in cardiopulmonary arrest, had a cardiac arrest 24 hours prior to admission to the MICU, or were on vasopressors for less than 3 hours.
The electronic medical record system was used to collect baseline demographic data, including age, sex, body mass index, race, past medical history, hospital length of stay, and MICU length of stay. The Charlson Comorbidity Index and Sequential Organ Failure Assessment (SOFA) score were calculated for all patients as a measure of comorbid conditions and disease severity. SOFA score was determined using the worst values in the first 24 hours of septic shock. Other prior-to-admission cardiovascular medications included amlodipine, diltiazem, angiotensin II receptor blockers (ARBs), and other antiarrhythmics. Because of minor differences in the mechanism of action between ACE inhibitors and ARBs and the potential to confound the results, prior-to-admission use of ARBs was not considered for inclusion into a study group.
Suspected site of infection was documented in the electronic medical record by the MICU team within 24 hours of the onset of septic shock and included pulmonary, genitourinary, intra-abdominal, and skin and soft-tissue infection (SSTI) and blood, clostridium difficile, fungal, viral, or coinfection (more than 1 suspected site of infection). Initial antimicrobials were considered appropriate if they (1) followed expert guideline recommendations for empirical therapy at the suspected site when the patient was culture negative or (2) provided adequate antimicrobial coverage if the organism was isolated on culture during antibiotic treatment.
For the primary outcome of cumulative vasopressor dose at 48 hours, vasopressors included norepinephrine, epinephrine, phenylephrine, and dopamine. Epinephrine, phenylephrine, and dopamine were converted to norepinephrine equivalents in concordance with the previously published literature: 100 µg dopamine equivalent to 1 µg norepinephrine, 1 µg epinephrine equivalent to 1 µg norepinephrine, and 2.2 µg phenylephrine equivalent to 1 µg norepinephrine. 13, 14 Cumulative vasopressor dose at 6, 12, and 24 hours of septic shock were also collected.
Other clinical information collected as secondary end points included peak lactate within the first 48 hours of septic shock, mechanical ventilation (MV), renal replacement therapy (RRT), and in-hospital mortality. Concomitant medications that can affect blood pressure included hydrocortisone, inotrope, crystalloid, albumin, dobutamine, and vasopressin. Vasopressin, because of its differing mechanism of action, was dosed at a flat rate of 0.03 U/min and assessed dichotomously as either being administered or not. Fluid resuscitation with at least 30 mL/kg at 6 hours was assessed. Total time on vasopressors was collected for all groups.
Statistical Analysis
Data analyses were performed using SPSS (v22.0, IBM Corp, Armonk, NY). Baseline characteristics of study groups were compared for categorical variables using the Pearson χ 2 test or likelihood ratio if the assumptions of the Pearson χ 2 test were broken: any cell with expected count less than 1 or greater than 20% of expected cell counts less than 5. A 4-factor Kruskal-Wallis test was utilized for the primary outcome of cumulative vasopressor dose at 48 hours and all other continuous variables. P values below 0.05 were considered statistically significant. Post hoc, pairwise group comparisons using a Bonferroni correction for adjusted P values were completed for variables with statistical significance.
An a priori power calculation was completed to estimate a sample size. 15 There was a smaller presented study that showed a dramatic decrease in norepinephrine dose in patients receiving β-blockers or ACE inhibitor prior to admission for patients in circulatory shock of any kind (the cumulative vasopressor dose in the group on antihypertensives prior to admission was 23.98 mg when compared with the group not on antihypertensives prior to admission 53.29 mg; P = 0.13). 16 Using these data, an estimated SD of 10, a 4-way fixed-effects ANOVA calculated effect size of 1.08, and 95% power, the total sample size required to demonstrate a difference between the 4 groups was n = 16. Because the previously presented study examined shock of any kind and not specifically septic shock, the anticipated effect was unknown, and an additional a priori power calculation with a medium effect (f = 0.25) and 80% power was estimated. Using these parameters, a total sample size of 180 patients was needed to detect a difference.
Results
Study Population
A total of 686 patients admitted to an ICU with a diagnosis of septic shock were screened for inclusion from January 2012 until August 2016 (Figure 1 ). Admission to an ICU other than the MICU or diagnosis of septic shock without vasopressor use were the 2 main reasons for exclusion. Included patients tended to be male (all median ages >60 years) without differences between race and ethnicity, although many patients were either white or black (Table 1) .
Past medical histories were similar between groups with the exception of hypertension, heart failure, atrial fibrillation/ arrhythmia, and moderate-to-severe liver disease. There was no difference in comorbidity present on admission as evi- 
Infection, Severity, and Mortality
Suspected sites of infections on presentation to the MICU were similar between all groups (Table 2) . Pulmonary (total Abbreviations: ACE-I, angiotensin-converting enzyme inhibitor; MICU, medical intensive care unit. n = 39, 29%) and genitourinary (total n = 33, 20%) sites were the 2 most prevalent suspected sites of infection across the 4 groups. Initial antimicrobials were appropriate in a high percentage (>70%) of patients in all 4 groups. 
All continuous variables are reported as median [IQR] and all categorical variables as n (%).
b Missing lactate levels: no β-blocker or ACE inhibitor (n = 2), β-blocker (n = 1), ACE inhibitor (n = 1), no β-blocker or ACE inhibitor (n = 0).
Length of stay was similar between groups, and there was no difference in the severity of disease reflected by the median SOFA score (no β-blocker or ACE inhibitor, 12 [ [10 to 16] ; P = 0.148). Median peak lactate was considered elevated in all groups (>2 mmol/L), and a high proportion of patients experienced in-hospital mortality (range between groups, 35%-58%).
Cumulative Vasopressor Dose and Total Time on Vasopressors
The primary outcome-cumulative vasopressor dose at 48 hours-was not statistically different between groups, even when adjusting for total body weight (Table 3) . Additionally, no difference in cumulative vasopressor dose was observed at a priori time points of 6, 12, and 24 hours. Total time (hours) on vasopressors differed between groups, with patients receiving chronic ACE inhibitor having the lowest median time (no β-blocker or ACE inhibitor, 30 [ 
Concomitant Therapies
Chronic amlodipine and antiarrhythmic use differed between treatment groups; however, the use of ARBs did not (Table 4) . Vasopressin use, at a flat dose of 0.03 U/min, was also statistically significantly different between groups (P = 0.017) with more than half of the β-blocker-only group having received vasopressin (n = 25, 54%). Dobutamine use, hydrocortisone use, 30 mL/kg of fluid resuscitation at 6 hours, MV, and RRT did not differ between the 4 groups.
Discussion
In this retrospective observational study of 133 patients with septic shock, patients who were on chronic β-blockers, ACE inhibitors, or both had no difference in cumulative vasopressor dose at 48 hours when compared with patients who were not on either chronic medication. Similarly, when adjusting vasopressor dose for body weight, no difference was observed at 48 hours. Chronic β-blockers and/or ACE inhibitor did not alter cumulative dose exposure at any collected time point (6, 12 , and 24 hours) within the first 48 hours of septic shock.
Time on vasopressors differed between the 4 groups, with the ACE inhibitor only group having the lowest statistically significant time, but all patients receiving chronic antihypertensives had less total time on vasopressors than patients not on antihypertensives prior to admission. Although this difference in secondary end point cannot be fully elucidated, the results could be partially explained by the 3 chronic antihypertensive groups having a higher percentage of patients with a past medical history of hypertension. As septic shock resolved, these patients may have begun autoregulation to their own chronic baseline blood pressure, which could have been higher than guideline-recommended defined mean arterial pressure (MAP) goals in septic shock (ie, MAP > 65 mm Hg). 1, 17, 18 However, in a study by Asfar et al 12 (SEPSISPAM study) in patients with septic shock who were randomized to either 1 of 2 goal blood pressure arms-MAP of 65 to 70 mm Hg (low-target group) or 80 to 85 mm Hg (high-target group) 12 -the authors found no difference in the primary outcome of 28-day mortality or secondary outcomes of need of MV, length of stay in the ICU and hospital, and SOFA score by day 7. Of note, there were a high proportion of patients in the low-target group (n = 173, 44.6%) and high-target group (n = 167, 43.0%) with chronic arterial hypertension; however, the median doses of norepinephrine on all days 1 through 5 between the low and high groups were statistically significant, and duration of catecholamine infusion differed (3.7 ± 3.2 mean days in the low-target group vs 4.7 ± 3.7 mean days in the high-target group; P < 0.001). The findings in the SEPSISPAM study make it difficult to conclude that the presence of a past medical history of hypertension alone is completely responsible for the decreased time on vasopressors observed in our study, although, its exact impact is unclear.
Other previous studies have demonstrated a survival benefit of acute β-blocker administration during septic shock after stabilization of cardiovascular function using vasopressor and fluid resuscitation therapies. In a previous open-label study of patients with severe septic shock and tachycardia after 24 hours, patients who received a continuous infusion of esmolol, a selective β-blocker, required less norepinephrine than a control group of patients who received conventional treatment. 9 Similarly, Schmittinger et al 19 reviewed their clinical experience providing enteral metoprolol in septic shock patients with suspected septic cardiomyopathy and found a decrease in norepinephrine requirements. In the current study, we aimed to determine if chronic administration of antihypertensive medications such as β-blockers and ACE inhibitors, chronic medications that potentially alter the receptor phenotypes and response to sympathetic overstimulation and immunomodulatory effects seen in septic shock, 6, 20, 21 could decrease the exposure to vasopressors, as evidenced by cumulative dose. Our results do not contradict the benefits of the acute administration of β-blockers after cardiovascular stabilization; however, receiving these medications prior to admission did not alter vasopressor exposure in the first 48 hours of septic shock.
Outpatient β-blocker prescriptions have been associated with increased survival. In a large pharmacoepidemiological database study looking at patients with a discharge diagnosis of sepsis, Macchia et al 7 described this association. However, this database study lacked risk stratification, source of infection, physiological measurements, or supportive therapies, including the use of vasopressors, and further challenge external generalizability because of regional differences in diet, exercise, and community health in the study population. In our current study, supportive and concomitant therapies used in the treatment of septic shock were similar between all 4 groups, with the exception of vasopressin. Our supportive measures, including implementation of stress dose steroids with hydrocortisone, inotrope use, fluid resuscitation within 6 hours, MV, and RRT, were similar between groups, making our findings more generalizable to patients presenting with septic shock.
Another recent study by Wiewel et al 22 revealed through subgroup analysis that chronic β-blocker or ACE inhibitor use did not decrease 30-day mortality. 22 However, only 29.4% (n = 58/197) of the patients evaluated in this subgroup experienced shock, whereas septic shock requiring vasopressor use was necessary for inclusion into our study. Additionally, disease severity was lower, as evidenced by a median SOFA score of 7 versus our current study, which had median SOFA scores >10 in all 4 groups. Even though their study was not powered to detect an association in 30-day mortality in patients on chronic β-blockers and ACE inhibitors and included less severe forms of sepsis, their findings support the idea that there may be no difference in outcomes (ie, mortality) in patients on chronic β-blockers and ACE inhibitors prior to admission. Furthermore, in-patient mortality in our current study correlated closely with historically published SOFA scores and serum lactate levels, further validating our findings, although these measures have only been validated to predict ICU mortality.
1,23,24
Limitations
Adherence to prescribed chronic β-blockers or ACE inhibitors could not be confirmed with the patient and is a limitation. However, chronic medications not only had to be listed on the patient's prior-to-admission medication list and reconciled by hospital staff, but investigators also reviewed the admission notes to search for specific mention of patient nonadherence.
The electronic medical record charting by the staff may be subject to inaccuracies in vasopressor dose infusion changes and documentation. Despite this, it is the medical center's policy for the nurse to document the total volume of vasopressor infused from the infusion pumps when new bags are hung, a new concentration started, and/or at change of shift. Similarly, clinical information such as suspected site of infection and Glasgow Coma Scale (GCS) was reliant on the electronic medical record notes and could not be confirmed in real time.
Power was reached using our initial a priori power calculation and Sokol et al 16 data; however, our observed effect was much less than previously observed. Inability to reach adequate patient numbers meant that statistical power was not achieved from our second a priori calculation using a medium effect size. This results in an increased chance of error, and therefore, a study with a larger sample is needed to confirm our results.
Finally, data were reviewed from 2012 to 2016, and this study did not account for changes in the management of septic shock, provider preference for fluid type, vasopressor type or order of administration, hydrocortisone dosing, emergence of resistant organisms, or new antimicrobials to come to market, although these treatments did not appear to differ greatly from current guideline recommendations and were equal between groups.
